These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 17989653)

  • 21. A proposal for financing postmarketing drug safety studies by augmenting FDA user fees.
    Carpenter D
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-469-80. PubMed ID: 16234281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Legal developments relevant to FDA authority.
    Meron D
    Food Drug Law J; 2007; 62(2):441-4. PubMed ID: 17632974
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA finalizing policy statement on industry-supported activities.
    Am J Hosp Pharm; 1993 Mar; 50(3):391. PubMed ID: 8442443
    [No Abstract]   [Full Text] [Related]  

  • 24. 'Must-pass' FDA fee renewal jammed with sunscreen and more.
    Scheinbaum C
    Nat Med; 2012 Jul; 18(7):990. PubMed ID: 22772529
    [No Abstract]   [Full Text] [Related]  

  • 25. Determinants of vaccine supply.
    Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
    [No Abstract]   [Full Text] [Related]  

  • 26. Painkiller in the dock.
    Nature; 2005 Jul; 436(7050):459. PubMed ID: 16049447
    [No Abstract]   [Full Text] [Related]  

  • 27. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
    Gatty B
    Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
    [No Abstract]   [Full Text] [Related]  

  • 28. New law aims to distance the FDA from the drug industry.
    Lenzer J
    BMJ; 2005 May; 330(7500):1106. PubMed ID: 15891225
    [No Abstract]   [Full Text] [Related]  

  • 29. Implications of the Lannett and Pharmadyne decisions.
    Vetrano AJ
    Am J Hosp Pharm; 1980 Apr; 37(4):537-40. PubMed ID: 7377217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. User fees advance in Congress.
    Gershon D
    Nature; 1992 Sep; 359(6393):261. PubMed ID: 1406918
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA to collect fees from drug companies.
    Minn Med; 1992 Nov; 75(11):46. PubMed ID: 1435650
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA denies petitions to restrict livestock drug use.
    Cima G
    J Am Vet Med Assoc; 2012 Jan; 240(2):129-30. PubMed ID: 22319839
    [No Abstract]   [Full Text] [Related]  

  • 33. Vouchers for FDA priority reviews.
    Spatz ID
    Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
    [No Abstract]   [Full Text] [Related]  

  • 34. Medical costs and the drug industry.
    Schwartz H
    Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA regulatory compliance reconsidered.
    Tobias C
    Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract]   [Full Text] [Related]  

  • 36. Pediatric Research Equity Act.
    J Natl Cancer Inst; 2004 Dec; 96(24):1810. PubMed ID: 15601636
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA regulation of off-label drug promotion under attack.
    Kesselheim AS; Mello MM; Avorn J
    JAMA; 2013 Feb; 309(5):445-6. PubMed ID: 23385267
    [No Abstract]   [Full Text] [Related]  

  • 38. Editorial: Some caveats for the FDA.
    Calif Med; 1973 Oct; 119(4):64-5. PubMed ID: 4749314
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA regulations and guidelines.
    Rothschild A
    J Parenter Sci Technol; 1990; 44(1):26-9. PubMed ID: 2313489
    [No Abstract]   [Full Text] [Related]  

  • 40. Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson.
    Woodcock J
    Drug Discov Today; 2004 Jul; 9(13):548-50. PubMed ID: 15203087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.